NCT02845323View on ClinicalTrials.gov

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 16, 2017

Primary Completion Date

July 31, 2026

Study Completion Date

December 31, 2026

Conditions
Urothelial CarcinomaBladder Cancer
Interventions
DRUG

Nivolumab in combination with Urelumab

Two cycles of Nivolumab Two cycles of Urelumab

DRUG

Nivolumab monotherapy

Two cycles of Nivolumab alone

Trial Locations (5)

10032

Columbia University Medical Center, New York

21205

Johns Hopkins Hospital, Baltimore

60637

University of Chicago, Chicago

80045

University of Colorado Cancer Center, Aurora

90095

UCLA Institute of Urologic Oncology, Los Angeles

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER